Yukai Xiang

Yukai Xiang

Auto-generated profile, based on publicly available information

Yukai Xiang

Department of general surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WYWen Ye
Wen Ye
CZChenlei Zheng
Chenlei Zheng
DYDinglai Yu
Dinglai Yu
FZFan Zhang
Fan Zhang
RPReguang Pan
Reguang Pan
MZMeng-Tao Zhou
Meng-Tao Zhou
Acute lung injury (ALI) is a critical event involved in the pathophysiological process of acute pancreatitis (AP). Many methods have been widely used for the treatment of AP-ALI, but few are useful during early inflammation. Lipoxin A4 (LXA4), a potent available anti-inflammatory and novel antioxidant mediator, has been extensively studied in AP-ALI, but its underlying mechanism as a protective mediator is not clear. This research was conducted to identify the possible targets and mechanisms involved in the anti-AP-ALI effect of LXA4. First, we confirmed that LXA4 strongly inhibited AP-ALI in mice. Next, using ELISA, PCR, and fluorescence detection to evaluate different parameters, LXA4 was shown to reduce the inflammatory cytokine production induced by AP and block reactive oxygen species (ROS) generation in vivo and in vitro. In addition, TNF-α treatment activated the nuclear factor E2-related factor 2 (Nrf2) signaling pathway and its downstream gene heme oxygenase-1 (HO-1) in human pulmonary microvascular endothelial cells (HPMECs), and LXA4 further promoted their expression. This study also provided evidence that LXA4 phosphorylates Ser40 and triggers its nuclear translocation to activate Nrf2. Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI. Overall, LXA4 attenuated the resolution of AP-induced inflammation and ROS generation to mitigate ALI, perhaps by modulating the Nrf2/HO-1 pathway. These findings have laid a foundation for the treatment of AP-ALI.

11 April 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
SYSuhui Yu
Suhui Yu
JXJianming Xie
Jianming Xie
YXYukai Xiang
Yukai Xiang
SDShengjie Dai
Shengjie Dai
DYDinglai Yu
Dinglai Yu
MZMeng-Tao Zhou
Meng-Tao Zhou
Our previous studies verified the potent anti-inflammatory effects against severe acute pancreatitis (SAP) of AT-Lipoxin A4 and their analogues. However, the anti-inflammatory effects of AT-Lipoxin A4 on SAP-associated lung injury are not thoroughly known. We used western blot, polymerase chain reaction (PCR), and immunofluorescence to investigate the downregulation of TNF-α signals in cellular and animal models of SAP-associated lung injury following AT-Lipoxin A4 intervention. In vitro, we found that AT-Lipoxin A4 markedly suppressed protein expression in TNF-α signals in human pulmonary microvascular endothelial cell, such as tumor necrosis factor receptor-associated factor 2 (TRAF2), TNF-R1-associated death domain (TRADD), receptor-interacting protein (RIP), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. Moreover, AT-Lipoxin A4 inhibited downstream signals activated by TNF-α, including NF-κB/p65, JNK/MAPK, and ERK/MAPK. In vivo, AT-Lipoxin A4 significantly decreased pathological scores of the pancreas and lungs and the serum levels of IL-6 and TNF-α. Immunofluorescence, western blotting, and real-time PCR assay showed that AT-Lipoxin A4 significantly attenuated the expression of TNF-R1, TRADD, TRAF2, and RIP in the lungs of SAP rats. In addition, the activation of NF-κB was also downregulated by AT-Lipoxin A4 administration as compared with SAP rats. AT-Lipoxin A4 could inhibit the production of proinflammatory mediators and activation of TNF-α downstream signals such as NF-κB and MAPK. Downregulation of TNF-α signals by AT-Lipoxin A4 may be a significant mechanism in the attenuation of SAP-associated lung injury.

23 April 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JZJie Zhang
Jie Zhang
KSkeqing shi
keqing shi
WHWeiguo Huang
Weiguo Huang
WWWanqing Weng
Wanqing Weng
ZZZhang Zhongjing
Zhang Zhongjing
MZMeng-Tao Zhou
Meng-Tao Zhou
Compelling lines of evidence indicate that DNA methylation of non-coding RNAs (ncRNAs) plays critical roles in various tumour progression. In addition, the differential methylation of ncRNAs can predict prognosis of patients. However, little is known about the clear relationship between DNA methylation profile of ncRNAs and the prognosis of pancreatic adenocarcinoma (PAC) patients. The data of DNA methylation, RNA-seq, miRNA-seq and clinical features of PAC patients were collected from TCGA database. The DNA methylation profile was obtained using the Infinium HumanMethylation450 BeadChip array. LASSO regression was performed to construct two methylation-based classifiers. The risk score of methylation-based classifiers was calculated for each patient, and the accuracy of the classifiers in predicting overall survival (OS) was examined by ROC curve analysis. In addition, Cox regression models were utilized to assess whether clinical variables and the classifiers were independent prognostic factors for OS. The targets of miRNA and the genes co-expressed with lncRNA were identified with DIANA microT-CDS and the Multi-Experiment Matrix (MEM), respectively. Moreover, DAVID Bioinformatics Resources were applied to analyse the functional enrichment of these targets and co-expressed genes. A total of 4004 CpG sites of miRNA and 11,259 CpG sites of lncRNA were screened. Among these CpG sites, 8 CpG sites of miRNA and 7 CpG sites of lncRNA were found with regression coefficients. By multiplying the sum of methylation degrees of the selected CpGs with these coefficients, two methylation-based classifiers were constructed. The classifiers have shown good performance in predicting the survival rate of PAC patients at varying follow-up times. Interestingly, both of these two classifiers were predominant and independent factors for OS. Furthermore, functional enrichment analysis demonstrated that aberrantly methylated miRNAs and lncRNAs are related to calcium ion transmembrane transport and MAPK, Ras and calcium signalling pathways. In the present study, we identified two methylation-based classifiers of ncRNA associated with OS in PAC patients through a comprehensive analysis of miRNA and lncRNA profiles. We are the first group to demonstrate a relationship between the aberrant DNA methylation of ncRNAs and the prognosis of PAC, and this relationship would contribute to individualized PAC therapy.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BLBi Lin
Bi Lin
YPYangyang Pan
Yangyang Pan
DYDinglai Yu
Dinglai Yu
SDShengjie Dai
Shengjie Dai
HSHongwei Sun
Hongwei Sun
CHChaohao Huang
Chaohao Huang
Background. Pancreatic cancer is one of the most malignant tumors of the digestive system, and its treatment has rarely progressed for the last two decades. Studies on m6A regulators for the past few years have seemingly provided a novel approach for malignant tumor therapy. m6A‐related factors may be potential biomarkers and therapeutic targets. This research is focused on the gene characteristics and clinical values of m6A regulators in predicting prognosis in pancreatic cancer. Methods. In our study, we obtained gene expression profiles with copy number variation (CNV) data and clinical characteristic data of 186 patients with pancreatic cancer from The Cancer Genome Atlas (TCGA) portal. Then, we determined the alteration of m6a regulators and their correlation with clinicopathological features using the log‐rank tests, Cox regression model, and chi‐square test. Additionally, we validated the prognostic value of m6A regulators in the International Cancer Genome Consortium (ICGC). Results. The results suggested that pancreatic cancer patients with ALKBH5 CNV were associated with worse overall survival and disease‐free survival than those with diploid genes. Additionally, upregulation of the writer gene ALKBH5 had a positive correlation with the activation of AKT pathways in the TCGA database. Conclusion. Our study not only demonstrated genetic characteristic changes of m6A‐related genes in pancreatic cancer and found a strong relationship between the changes of ALKBH5 and poor prognosis but also provided a novel therapeutic target for pancreatic cancer therapy.

11 March 2021 in Chronobiology International
Verified
Journal Article
Closed access
LZLe-Le Zhang
Le-Le Zhang
QHQi-Kuan He
Qi-Kuan He
YLYan-Ning Lv
Yan-Ning Lv
ZZZhong-Jing Zhang
Zhong-Jing Zhang
YXYu-Kai Xiang
Yu-Kai Xiang
Accumulating studies indicate that circadian clock genes are pivotal regulators of tumorigenesis and development of various cancers. Nevertheless, their implications in pancreatic adenocarcinoma (PAAD) remain poorly characterized. We investigated the expression pattern of circadian clock genes and evaluated their prognostic values in PAAD. Firstly, we systematically analyzed data from The Cancer Genome Atlas (TCGA) database pertaining to patient clinical information and gene expression data. We found that 19 of 20 circadian clock genes showed significantly different expression levels in comparisons between PAAD and normal tissues. In addition, 10 circadian clock genes with regression coefficients were selected to construct a new risk signature, which was then identified as an independent prognostic factor for PAAD. Mechanistically, circadian clock genes in PAAD may impact the basic state of cells and the composition of tumor-infiltrating immune cells, thus affecting disease prognosis. Finally, we construct a novel prognostic nomogram on the basis of histological nodes and risk score to precisely predict prognosis of patients with PAAD. In conclusion, our study uncovered the important role of circadian clock genes in PAAD and developed a risk signature as a promising prognostic biomarker for patients with PAAD.

16 June 2020 in Research Square
Verified
Preprint
Open access
PDF file
QHQikuan He
Qikuan He
PGPengyi Guo
Pengyi Guo
YLYunshou Lin
Yunshou Lin
ZZZhongjing Zhang
Zhongjing Zhang
YLYanning Lv
Yanning Lv
YXYukai Xiang
Yukai Xiang
Background: Circadian clock genes have been reported to exhibit a regulatory effect on the carcinogenesis and progression of numerous cancers. Nevertheless, the specific relationship between hepatocellular carcinoma (HCC) and circadian rhythm associated genes still remain to be clarified. Therefore, we evaluate the prognosis function of circadian clock genes in HCC with the online datasets of The Cancer Genome Atlas (TCGA) and the international cancer genome consortium (ICGC). Methods: In our research, the RNA-seq of the selected core circadian genes in HCC patients and their relevant clinical data were acquired from the online TCGA database and the ICGC database. R software and cBioPortal website were performed. Results: As consequence, among the 22 typical circadian clock genes, 16 genes were statistically expressed between HCC and adjacent normal tissues. Accordingly, 11 clock genes with regression coefficients were used to constitute a new risk score formula, which was related to the prognosis in HCC. Moreover, the new nomogram, which consisting risk score and several clinical traits , could be applied for the purpose of accurate prediction of the OS time for the patients. Finally, we identified a novel nomogram related with OS in HCC patients with a comprehensive analysis of circadian clock genes and other clinical characteristics profiles. It was also the first time we systematically demonstrated the relationship between clock genes and the HCC prognosis, which would contribute to the treatment of HCC. Conclusions: The current study demonstrated the potential of circadian clock genes as clinically associated biomarkers for prognosis prediction in HCC, which may make a significant contribution to the further investigations of HCC progression.